Mr. Aldrich is a co-founder and Partner of Longwood Fund. He has co-founded and helped to build several successful biotech companies including Sirtris Pharmaceuticals (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008), Concert Pharmaceuticals (NASDAQ: CNCE), where he serves as Chairman of the Board of Directors and Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), Verastem (NASDAQ: VSTM), where he serves on the Board of Directors, and OvaScience (NASDAQ: OVAS), where he serves as Chairman of the Board of Directors. Mr. Aldrich also serves on the Board of Directors of Longwood portfolio companies PTC Therapeutics (NASDAQ: PTCT) and Mitokyne, Inc. Mr. Aldrich also serves on the Board of Directors at Tempero Pharmaceuticals. Prior to co-founding Longwood, he was General Partner of RA Capital, a biotechnology investment fund he founded in 2001. Mr. Aldrich was also a founding employee of Vertex Pharmaceuticals (NASDAQ: VRTX) where he held the position of Senior Vice President and Chief Business Officer and managed all commercial and operating functions from 1989 to 2001. Prior to joining Vertex, Mr. Aldrich held several management positions at Biogen, Inc. Mr. Aldrich serves on the Board of the Massachusetts Eye & Ear Infirmary and the Greater Boston YMCA. Mr. Aldrich received his undergraduate degree from Boston College, and an MBA from the Amos Tuck School at Dartmouth College.
Dr. Dipp is a co-founder and Partner of Longwood Fund. Dr. Dipp currently serves as the CEO and co-founder of OvaScience (NASDAQ: OVAS), a Longwood portfolio company. Dr. Dipp also co-founded Longwood portfolio companies Alnara Pharmaceuticals and Verastem (NASDAQ: VSTM). Previously, Dr. Dipp was the Senior Vice President and Head of GSK’s Centre of Excellence for External Drug Discovery (CEEDD). Prior to leading GSK’s CEEDD, Dr. Dipp was the Vice President of Corporate Development at Sirtris (NASDAQ: SIRT acquired by GlaxoSmithKline in 2008). Dr. Dipp led the successful acquisition of Sirtris by GSK in June 2008 for $720 million. Before joining Sirtris as a founding employee, she worked in healthcare private equity at The Wellcome Trust, London. Dr. Dipp holds an MD from Oxford University Medical School and a PhD in Physiology from the University of Oxford. Dr. Dipp did her post-doctoral research in the departments of Pharmacology and Cardiothoracic Surgery, John Radcliffe Hospital, Oxford. Dr. Dipp serves on the Beth Israel Deaconess Medical Center Board of Trustees, the Boston Symphony Orchestra Board of Overseers, and the Board of Directors of the City on a Hill Charter School in Roxbury, Mass.
Dr. Westphal is a co-founder and Partner of Longwood Fund, which founds and invests in medical companies. Dr. Westphal currently serves as the co-founder, CEO and Chairman of Longwood portfolio company FlexPharma and co-founder, former CEO, and Executive Chairman of Longwood portfolio company Verastem (NASDAQ: VSTM). Dr. Westphal also co-founded Longwood portfolio companies Alnara Pharmaceuticals (acquired by Eli Lilly in 2010), and OvaScience (NASDAQ: OVAS), where he also serves on the Board of Directors. In addition, he co-founded Sirtris in 2004 (NASDAQ: SIRT; acquired by GSK), and served as CEO until 2010. Dr. Westphal previously served as co-founder/CEO of Alnylam Pharmaceuticals (NASDAQ: ALNY), Acceleron Pharmaceuticals (NASDAQ: XLRN) and Momenta Pharmaceuticals (NASDAQ: MNTA). Companies founded by Dr. Westphal have invented important drugs, including the largest-selling heparin in the US, and several experimental medicines: for cystic fibrosis (phase 3), for currently incurable cancers (phase 2), and for serious inflammatory disorders (phase 2). In addition, these companies have created substantial shareholder value and aggregate market capitalizations (sustained) of over $6 billion. Dr. Westphal serves on the Board of Fellows of Harvard Medical School, and the Board of Overseers of the Boston Symphony Orchestra. He earned his M.D. from Harvard Medical School and Ph.D. in genetics from Harvard University and he graduated with a B.A. summa cum laude and Phi Beta Kappa from Columbia University. Dr. Westphal has been the lead or senior author on several patent applications and scientific papers in leading journals such as Cell, Nature and Nature Genetics. Dr. Westphal has been featured in the media, including on ‘60 Minutes’, CNN, an ABC News Special hosted by Barbara Walters, and as the subject of a Fortune cover article.
Managing Partner and CEO of the Boston Celtics
Peter Hutt, LLB, LLM
Former FDA General Counsel, SAB: Sirtris, Alnara, OvaScience (NASDAQ: OVAS), BOD: Momenta (NASDAQ: MNTA)
Fidelity Investments Inc., Investor Sirtris (NASDAQ: SIRT, now GSK)
John Maraganore, PhD
CEO Alnylam (NASDAQ: ALNY)
Brian McVeigh, CPA, CMA, CLP, MBA
GlaxoSmithKline, Vice President, WWBD Transactions and Investment Management
Chairman and Chief Executive Officer Alkermes (NASDAQ: ALKS), BOD: Sirtris (NASDAQ: SIRT, now GSK)
Paul Schimmel, PhD
NAS, Scripps, Co-Founder Alnylam (NASDAQ: ALNY), Momenta (NASDAQ: MNTA) and Sirtris (NASDAQ: SIRT, now GSK)
Phil Sharp, PhD
Nobel Prize, Co-Founder Biogen and Alnylam (NASDAQ: ALNY), NAS, SAB: Sirtris (NASDAQ: SIRT, now GSK), Verastem (NASDAQ: VSTM)
David Sinclair, PhD
Harvard, Co-Founder/SAB: Sirtris (NASDAQ: SIRT, now GSK), OvaScience (NASDAQ: OVAS)
Moncef Slaoui, PhD
GlaxoSmithKline, Chairman R&D
Former Chairman, President and CEO Genzyme, BOD: Verastem (NASDAQ: VSTM)
Chris Walsh, PhD
Harvard, NAS, Genzyme, SAB: Sirtris (NASDAQ: SIRT, now GSK), Verastem (NASDAQ: VSTM), FlexPharma
SAB = Scientific Advisory Board, BOD = Board of Directors, NAS = National Academy of Sciences